SAGE Therapeutics Inc

NASDAQ:SAGEUnited States

Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

Contact Information

Headquarters

215 1st StCAMBRIDGE, MA, United States 02142-1213

Phone

617-299-8380

Fax

617-299-8379

Executives

Independent Chairman of the Board

Geno Germano

Director

Barry Greene

Chief Financial Officer, Treasurer

Kimi Iguchi

Senior Vice President, General Counsel

Anne Cook

Chief Scientific Officer

Mike Quirk